Le Lézard
Classified in: Health
Subjects: SCZ, CPG

New results: Province-wide expansion of innovative program helps improve lives of New Brunswick seniors living with dementia


FREDERICTON, Feb. 5, 2019 /CNW/ - Today, the Canadian Foundation for Healthcare Improvement (CFHI), the New Brunswick Association of Nursing Homes (NBANH) and Government of New Brunswick have announced results of a successful province-wide expansion of person-centred dementia care to all 68 nursing homes organizations in New Brunswick. Over the two phases of the program, more than half of participating residents who were prescribed antipsychotics without a diagnosis of psychosis had these medications safely reduced or discontinued.

Jenny, Director of Care at Orchard View Long Term Care Facility and Elsie, a resident at the home, interact with ROVER, a multisensory therapy cart. ROVER provides a soothing and stimulating immersive environment to residents with dementia. The cart is portable and gives residents a sense of calm and control by delivering stimuli to various senses using lighting effects, colour, sounds, vibration, music, scents, and things to touch. (CNW Group/Canadian Foundation for Healthcare Improvement)

Through the New Brunswick Appropriate Use of Antipsychotics (AUA) Collaborative, which began in May 2016, nursing home staff identified residents who could benefit from non-drug therapies to treat symptoms related to dementia. Using a person-centred approach to care, staff engaged residents and their families in developing approaches to care that reflect the resident's preferences and that ensure the resident feels safe and comfortable. This included offering therapies and recreational activities that are meaningful and enjoyable, like exercise, pet or music therapy.

Final results of the initiative included:

Over half a million Canadians live with dementia, with 25,000 new cases diagnosed every year. Antipsychotic medications are often prescribed to help manage symptoms related to dementia, such as agitation and aggression. However, there is a lack of evidence to support their effectiveness for this purpose and a risk that they can cause significant side effects such as confusion, dizziness and stroke. By reducing the inappropriate use antipsychotics, residents in long term care tend to be better able to eat independently, and are more wakeful, which benefits residents, families, and staff.

Rates of potentially inappropriate antipsychotic use to manage symptoms of dementia continue to fall across Canada thanks to the efforts of providers, provincial health quality councils, associations, governments and many others in New Brunswick and elsewhere who are expanding appropriate use of antipsychotics programs. In 2013-2014, about 1 in 3 (30 percent) long term care residents who did not have a psychosis diagnosis was prescribed an antipsychotic. By 2017-2018, that number had dropped to 1 in 5 (21 percent).

*Of those still participating in the program at the end of Phase 1 and Phase 2.

Since 2014, CFHI has supported 191 long term care organizations from across Canada to improve the appropriate use of antipsychotic medication and the quality of life for residents through a pan-Canadian collaboration, as well as major provincial scale collaborations in New Brunswick, Quebec, Newfoundland and Labrador, and Prince Edward Island.

Quick facts

Quotes

"The Government of Canada is pleased to support CFHI's evidence-based approach to ensuring the appropriate use of prescription antipsychotic drugs for seniors, especially those living in nursing homes," said the Honourable Ginette Petitpas Taylor, federal Minister of Health. "This innovative program demonstrates how focusing on person-centered care can improve the lives of Canadians with dementia, as well as the lives of their families and loved ones."

"We're delighted to celebrate New Brunswick's leadership in improving care of people living with dementia. Residents, along with their families, nursing home staff, and other partners are working together to spread proven approaches to care that promote appropriate medication use," said Jennifer Zelmer, President and CEO of CFHI. "The results show clearly that these efforts are improving care and quality of life in nursing homes across the province."

"We are extremely pleased to have played a supporting role with CFHI and the Government of New Brunswick in bringing this innovation opportunity to New Brunswick Nursing Homes," said Jodi Hall, Executive Director of the New Brunswick Association of Nursing Homes. "The nursing home teams fully embraced the process for this care improvement, and we congratulate them on their leadership and staff commitment. It is very exciting to see the residents experience an improved quality of life."

For more information: http://www.cfhi-fcass.ca/WhatWeDo/appropriate-use-of-antipsychotics

About the Canadian Foundation for Healthcare Improvement
CFHI works shoulder-to-shoulder with partners to identify proven innovations and accelerate their spread across Canada, improving patient care, the health of everyone in Canada and value-for-money. CFHI is a not-for-profit organization funded by Health Canada. Visit cfhi-fcass.ca for more information.

About the New Brunswick Association of Nursing Homes
Leading excellence in long term care, the mission of the New Brunswick Association of Nursing Homes is to lead member homes through a united voice by advocating excellence in long term care and service delivery in New Brunswick.

The views expressed herein do not necessarily represent the views of Health Canada.

 

SOURCE Canadian Foundation for Healthcare Improvement


These press releases may also interest you

at 05:29
SmartCella Holding AB today announces that Dr Ricardo Baptista has been appointed Chief Technology Officer (CTO) and Head of Procella. Ricardo is an experienced Biochemical Engineer with almost 20-years of global experience in the medical...

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...



News published on and distributed by: